ASCLETIS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.35 HKD | -2.88% |
|
-4.93% | -7.53% |
| 04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
| 04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASCLETIS PHARMA INC. | Biopharmaceuticals | -2.88% | -4.93% | -7.53% | -43.51% | -78.08% | 175M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- 1672 Stock
- Charts Ascletis Pharma Inc.
- Comparison Chart
